An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Results from CAH Treatment Trials On December 11, Spruce Biosciences, Inc., announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Spruce is a late-stage...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * First Successful Clinical Trial with Anti-CD40L Antibody is Completed On October 29, a potentially major advancement for type 1 diabetes treatment was announced by the University of Miami Diabetes Research Institute (UM-DRI), in collaboration with the University of Chicago, regarding the...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Treatment of Hypertension On October 15, Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two phase III Trials in MASH for Survodutide On October 8, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Priority Review Granted for HER2-low or HER2-ultralow Metastatic Breast Cancer Treatment On October 1, AstraZeneca and Daiichi Sankyo announced that its supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the...
